AskBorsa

SPINALEX results, Q2 2023

Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.

Net profit12.68 millionEGP · +272.2% vs the same period a year earlier
Total assets698 millionEGP · −5.6% vs the same period a year earlier
Shareholders' equity613 millionEGP · +7.6% vs the same period a year earlier
Operating cash flow2.7 millionEGP · +110.1% vs the same period a year earlier

In short

  • SPINALEX's net profit for Q2 2023 was about 12.68 million EGP, up +272.2% from 3.41 million EGP in Q2 2022.
  • Total assets at the end of Q2 2023 were about 698 million EGP, and shareholders' equity about 613 million EGP.
  • Operating cash flow for Q2 2023 was positive at 2.7 million EGP.
Source: the Q2 2023 financial statements

Key lines against the same period a year earlier

This periodQ2 2022Change
Net profit12.68 million3.41 million+272.2%
Gross profit15.16 million9.12 million+66.2%
Total assets698 million739 million−5.6%
Total liabilities85.11 million170 million−49.9%
Shareholders' equity613 million570 million+7.6%
Total liabilities and equity698 million739 million−5.6%
Operating cash flow2.7 million-26.75 million+110.1%
Investing cash flow4.8 million52.27 million−90.8%
Financing cash flow-3.9 million-2.22 million−75.4%
Net change in cash3.6 million23.3 million−84.5%

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.

The report file for this period has not been published yet.All of SPINALEX's statements, five yearsAsk the AI analyst about SPIN

SPINALEX's Fiscal year 2026 results, the day they are published

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

Other periods for SPINALEX